US00507W2061
© PR Newswire
23.06.2025
ATNM
LISTED
XASE
Actinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at the Society of Nuclear Medicine &
News Preview
- ATNM-400 shows; superior prostate cancer cell killing compared to androgen receptor inhibitor Xtandi® (enzalutamide), the ability to overcome Xtandi resistance, and activity in combination
- ATNM-400 is more efficacious than both Pluvicto® (177-Lu-PSMA-617) and Ac-225-PSMA-617 targeted radiotherapy in prostate cancer in vitro and in vivo mode...
Themefolio
Profiler
Peergroup
© BusinessWire
27.05.2025
ATNM
LISTED
XASE
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium
News Preview
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Actinium Pharmaceuticals, Inc. (“Actinium” or the “Company”) (NYSE: ATNM) and reminds investors of the May 26, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
F...
Themefolio
Profiler
Peergroup
© BusinessWire
23.05.2025
ATNM
LISTED
XASE
ATNM Deadline: Rosen Law Firm Urges Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
News Preview
Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of securities of Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) between October 31, 2022, and August 2, 2024. Actinium describes itself as a “late-stage biopharmaceutical company that develops targeted radiothe...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© PR Newswire
06.05.2025
ATNM
LISTED
XASE
Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center
News Preview
- Initial clinical data expected in the second half of 2025 from this first-of-its-kind trial to administer a targeted radiotherapy conditioning agent with a commercial CAR-T therapy
- Iomab-ACT supported by results of NIH funded trial with MSK showing effective lymphodepletion of targeted immune cells resulting in negligible rates of...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
28.04.2025
ATNM
LISTED
XASE
Actinium Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models at the American Association for Cancer Research Annual Meeting
News Preview
- Results highlight ATNM-400's potential as a transformative therapeutic option for prostate cancer patients with unmet clinical needs as expression of the target receptor for ATNM-400 persists following Pluvicto therapy and ATNM-400 demonstrates sustained tumor control after Pluvicto stops working
- ATNM-400 showed greater tumor growth inhibit...
Themefolio
Profiler
Peergroup
© PR Newswire
28.04.2025
ATNM
LISTED
XASE
Actinium Highlights Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute Myeloid Leukemia Treatment at the American Association for Cancer Research Annua
News Preview
Actimab-A significantly potentiated and prolonged efficacy in combination with standard of care targeted therapies including hypomethylating agent azacitidine, FLT3 and menin inhibitors in in-vivo AML modelsActimab-A is the only CD33 targeted radiotherapy with Actinium-225 isotope payload in development for AML and other myeloid malignanciesActim...
Themefolio
Profiler
Peergroup
© PR Newswire
14.04.2025
ATNM
LISTED
XASE
With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz
News Preview
Equity Insider News Commentary
Issued on behalf of Oncolytics Biotech Inc.
VANCOUVER, BC, April 14, 2025 /PRNewswire/ -- Equity Insider News Commentary – Routine medical appointments or cancer screenings—critical for catching the disease in earlier, more treatable stages—has dropped to just over 50% of the population. At the same time, doctors ar...
Themefolio
Profiler
Peergroup
© PR Newswire
14.04.2025
ATNM
LISTED
XASE
With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz
News Preview
Equity Insider News Commentary
Issued on behalf of Oncolytics Biotech Inc.
VANCOUVER, BC, April 14, 2025 /CNW/ -- Equity Insider News Commentary – Routine medical appointments or cancer screenings—critical for catching the disease in earlier, more treatable stages—has dropped to just over 50% of the population. At the same time, doctors are raisi...
Themefolio
Profiler
Peergroup
© PR Newswire
14.04.2025
ATNM
LISTED
XASE
With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz
News Preview
Equity Insider News Commentary
Issued on behalf of Oncolytics Biotech Inc.
VANCOUVER, BC, April 14, 2025 /PRNewswire/ -- Equity Insider News Commentary – Routine medical appointments or cancer screenings—critical for catching the disease in earlier, more treatable stages—has dropped to just over 50% of the population. At the same time, doctors ar...
Themefolio
Profiler
Peergroup
© BusinessWire
31.03.2025
ATNM
LISTED
XASE
Securities Fraud Investigation Into Actinium Pharmaceuticals, Inc. (ATNM) Announced – Investors Who Lost Money Urged to Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
News Preview
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Actinium Pharmaceuticals, Inc. (“Actinium” or the “Company”) (NYSE American: ATNM) investors concerning the Company’s possible violations of the federal securities laws.
IF YOU ARE AN INVESTOR WHO LO...
Themefolio
Profiler
Peergroup
© BusinessWire
31.03.2025
ATNM
LISTED
XASE
Actinium Pharmaceuticals, Inc. (ATNM) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
News Preview
Law Offices of Howard G. Smith announces an investigation on behalf of Actinium Pharmaceuticals, Inc. (“Actinium” or the “Company”) (NYSE American: ATNM) investors concerning the Company’s possible violations of federal securities laws.
IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN ACTINIUM PHARMACEUTICALS, INC. (ATNM), CONTACT THE LAW OFFICES OF...
Themefolio
Profiler
Peergroup
© BusinessWire
28.03.2025
ATNM
LISTED
XASE
Rosen Law Firm Urges Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
News Preview
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) between October 31, 2022, and August 2, 2024. Actinium describes itself as a “late-stage biopharmaceutical company that develops targeted radiotherapies.”...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
28.03.2025
ATNM
LISTED
XASE
Securities Fraud Investigation Into Actinium Pharmaceuticals, Inc. (ATNM) Announced – Investors Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz
News Preview
The Law Offices of Frank R. Cruz announces an investigation of Actinium Pharmaceuticals, Inc. (“Actinium” or the “Company”) (NYSE American: ATNM) on behalf of investors concerning the Company’s possible violations of federal securities laws.
IF YOU ARE AN INVESTOR WHO LOST MONEY ON ACTINIUM PHARMACEUTICALS, INC. (ATNM), CLICK HERE TO INQUIRE ABOU...
Themefolio
Profiler
Peergroup
© BusinessWire
28.03.2025
ATNM
LISTED
XASE
ATNM Investors Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Actinium Pharmaceuticals, Inc. (“Actinium” or “the Company”) (NYSE American: ATNM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchan...
Themefolio
Profiler
Peergroup
© BusinessWire
27.03.2025
ATNM
LISTED
XASE
Scott+Scott Attorneys at Law LLP Files Securities Class Action Against Actinium Pharmaceuticals, Inc. (NYSE American: ATNM)
News Preview
Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, has filed a securities class action lawsuit in the United States District Court for the Southern District of New York against Actinium Pharmaceuticals, Inc. (“Actinium” or the “Company”) (NYSE American: ATNM), and certain of its form...
Themefolio
Profiler
Peergroup
© PR Newswire
27.03.2025
ATNM
LISTED
XASE
Actinium Pharmaceuticals Announces ATNM-400 a Novel Non-PSMA Targeting First in Class Prostate Cancer Radiotherapy Leveraging Actinium-225
News Preview
- 99.8% tumor growth inhibition achieved with a single dose of ATNM-400 in preclinical prostate cancer models
- ATNM-400 accumulated in tumors for up to 144 hours and showed minimal uptake in healthy tissues in prostate cancer xenograft model
- Initial ATNM-400 preclinical data to be presented at AACR including results in Pluvicto resistant pro...
Themefolio
Profiler
Peergroup
© PR Newswire
27.03.2025
ATNM
LISTED
XASE
Actinium Pharmaceuticals Provides Business Update After Presentation at Trump Mar-A-Lago Club Announcing Novel Non-PSMA Prostate Cancer Radiotherapy ATNM-400 and Outlining Revitalized Clinical Pipeline with 2025 Corporate Objectives
News Preview
- ATNM-400 is a novel, non-PSMA targeting, first-in-class Actinium-225 radiotherapy for prostate cancer with initial preclinical results to be presented at the AACR Annual Meeting
- Actinium is establishing radiopharmaceutical manufacturing infrastructure in 2025 to support expanding clinical trials and to leverage its proprietary Actinium-225 cy...
Themefolio
Profiler
Peergroup
© PR Newswire
26.03.2025
ATNM
LISTED
XASE
Actinium Pharmaceuticals to Present Business Update at Trump Mar-A-Lago Club Today
News Preview
- Company to highlight recent significant progress made with its Actimab-A and Iomab-ACT clinical programs, leading-edge R&D and radiopharmaceutical manufacturing infrastructure
- Revitalized clinical programs focused on 3 separate multi-billion-dollar market opportunities in myeloid malignancies, solid tumors and cell & gene therapy cond...
Themefolio
Profiler
Peergroup
© PR Newswire
25.03.2025
ATNM
LISTED
XASE
Actinium Pharmaceuticals to Host KOL Investor Call at 8am ET Today to Highlight Revamped Clinical Programs and Expanded Market Opportunities Including Newly Initiated Actimab-A Solid Tumor Program
News Preview
- Actinium will present 3 separate multi-billion-dollar market opportunities for Actimab-A and Iomab-ACT in myeloid malignancies, solid tumors and cell & gene therapy conditioning
- Dr. Ehab Atallah, Professor of Medicine at the Medical College of Wisconsin to highlight Actimab-A clinical results, mutation agnostic mechanism and b...
Themefolio
Profiler
Peergroup
© PR Newswire
24.03.2025
ATNM
LISTED
XASE
Actinium Pharmaceuticals Announces Supply Agreement with Eckert & Ziegler for Ac-225 Radioisotope to Support Comprehensive Development Activities
News Preview
NEW YORK, March 24, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced it has entered into an agreement for the supply of Actinium-225 (Ac-225) with Eckert & Ziegler. Under this agreement, Actinium Pharmaceuticals will ha...
Themefolio
Profiler
Peergroup
© PR Newswire
20.03.2025
ATNM
LISTED
XASE
Actinium Pharmaceuticals Announces Research Collaboration with Memorial Sloan Kettering to Support Further Clinical Expansion of Actimab-A's Backbone Therapy Strategy
News Preview
NEW YORK, March 20, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced that is has entered into a sponsored research agreement with Memorial Sloan Kettering Cancer Center (MSKCC) to expand Actimab-A's mutation agnostic mechan...
Themefolio
Profiler
Peergroup
© PR Newswire
19.03.2025
ATNM
LISTED
XASE
Actinium Pharmaceuticals to Host Investor KOL Call with Dr. Ehab Atallah of the Medical College of Wisconsin and Provide a Pipeline Update Highlighting Revamped Clinical Programs and Expanded Market Opportunities for Actimab-A and Iomab-ACT with Clinical
News Preview
- Actinium to highlight 3 separate multi-billion-dollar market opportunities for Actimab-A and Iomab-ACT in myeloid malignancies, solid tumors and cell & gene therapy conditioning
- Clinical proof of concept data expected in 2H:2025 from Actimab-A combination with blockbuster immunotherapies KEYTRUDA® and OPDIVO® in solid tumor indicati...
Themefolio
Profiler
Peergroup
© PR Newswire
18.03.2025
ATNM
LISTED
XASE
Actinium Pharmaceuticals Announces Clinical Trial Program in Solid Tumors Combining Actimab-A with PD-1 Checkpoint Inhibitors KEYTRUDA® and OPDIVO®
News Preview
- Trials are designed to demonstrate whether the addition of Actimab-A to either KEYTRUDA® or OPDIVO® can result in improved patient outcomes
- MDSCs – Myeloid Derived Suppressor Cells in the tumor microenvironment are believed to reduce effectiveness of PD-1 inhibitors like KEYTRUDA® and OPDIVO®
- Trials supported by preclinica...
Themefolio
Profiler
Peergroup
© PR Newswire
17.03.2025
ATNM
LISTED
XASE
Actinium Pharmaceuticals Announces Publication of Actimab-A + CLAG-M Trial Results in Patients with Relapsed or Refractory Acute Myeloid Leukemia in the Peer-Reviewed Journal Leukemia
News Preview
- Median Overall Survival of 18.4 months with Actimab-A + CLAG-M in patients with relapsed or refractory AML who received 1 or 2 lines of prior therapy
- Mutation agnostic potential of Actimab-A demonstrated by high rates of Complete Remissions and Measurable Residual Disease Negativity in patients with high-risk features including TP...
Themefolio
Profiler
Peergroup
© PR Newswire
12.03.2025
ATNM
LISTED
XASE
Actinium Pharmaceuticals to Participate at the 37th Annual Roth Conference
News Preview
NEW YORK, March 12, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced it will participate at the 37th Annual Roth Conference on March 16th to 18th....
Themefolio
Profiler
Peergroup
© PR Newswire
11.03.2025
ATNM
LISTED
XASE
Actinium Pharmaceuticals Announces Initiation of Actimab-A Triplet Combination Frontline Trial Under NCI CRADA with Venetoclax and Taiho Oncology's Hypomethylating Agent ASTX-727 in Patients with Newly Diagnosed AML
News Preview
Represents first ever triplet combination using targeted radiotherapy as a backbone therapy in AML with initial clinical data expected in 2H:2025Expansion into frontline setting greatly expands potential addressable patient opportunity for Actimab-ATriplet combination supported by previously completed Phase 1 trials of Actimab-A + Venetoclax and...
Themefolio
Profiler
Peergroup
© PR Newswire
18.11.2024
ATNM
LISTED
XASE
Actinium Pharmaceuticals Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024
News Preview
- Aligned with FDA on operationally seamless Phase 2/3 trial for Actimab-A + CLAG-M in relapsed/refractory acute myeloid leukemia
- Actimab-A selected for National Cancer Institute's recently opened myeloMATCH precision medicines program for patients with acute myeloid leukemia and myelodysplastic syndromes
- Two Iomab-ACT INDs cleared by FDA:...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2024
ATNM
LISTED
XASE
Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors
News Preview
- Dr. Almenoff brings more than 25 years of drug development and leadership
experience to the Actinium Board of Directors
- Dr. Almenoff to join Actinium's Nominating and Corporate Governance Committee
NEW YORK, Nov. 4, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, I...
Themefolio
Profiler
Peergroup
© PR Newswire
20.09.2024
ATNM
LISTED
XASE
Actinium Pharmaceuticals Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in the Journal of Clinical Oncology
News Preview
Iomab-B is the first CD45 targeted radiotherapy for conditioning in development to enable potentially curative bone marrow transplant and represents an alternative to chemotherapy-based approachesSIERRA achieved durable Complete Remission primary endpoint and Event-Free Survival secondary endpoint with high statistical significanceIomab-B was wel...
Themefolio
Profiler
Peergroup
© PR Newswire
05.08.2024
ATNM
LISTED
XASE
Actinium Provides Regulatory Update on Planned BLA Filing and Future Plans for Iomab-B in the U.S.
News Preview
FDA determined that the Phase 3 SIERRA trial is not adequate to support a BLA filing for Iomab-B despite its statistically significant primary endpointAdditional head-to-head randomized clinical trial demonstrating overall survival benefit with Iomab-B is required by FDA to support a BLA filingActinium to request a meeting with the FDA to further...
Themefolio
Profiler
Peergroup
© PR Newswire
01.08.2024
ATNM
LISTED
XASE
Actinium Expands Patent Coverage Over Iomab-ACT, its Next-Generation Targeted Radiotherapy Conditioning Agent, for Gene Edited Stem Cell-Based Therapies for Non-Malignant Indications
News Preview
- Newly issued U.S. patent augments Actinium's existing composition of matter patent coverage over Iomab-B and Iomab-ACT targeted radiotherapy conditioning programs
- Pertains to the use of Iomab-ACT with genetically engineered hematopoietic stem cells for treating non-malignant diseases including sickle cell disease, severe combined...
Themefolio
Profiler
Peergroup
© PR Newswire
25.07.2024
ATNM
LISTED
XASE
Actinium Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for Sickle Cell Disease Patients Undergoing Bone Marrow Transplant in Collaboration with Columbia University
News Preview
- Sickle cell disease affects approximately 100,000 patients in the U.S. annually and is a debilitating and life-threatening condition with high unmet need
- Current conditioning with non-targeted chemotherapies provides limited access to potentially curative bone marrow transplant and recently approved gene therapies for sickle cell disease pati...
Themefolio
Profiler
Peergroup
© PR Newswire
25.07.2024
ATNM
LISTED
XASE
Actinium Pharmaceuticals to Present at the 3rd Annual Targeted Radiopharmaceuticals Summit US
News Preview
Presentation to highlight positive outcomes of Iomab-B led bone marrow transplant in difficult to treat TP53 patients and the mutation-agnostic mechanism of Actimab-A for patients with relapsed or refractory acute myeloid leukemiaIomab-B and Actimab-A represent the only clinical stage antibody radiation conjugates in development for patients with...
Themefolio
Profiler
Peergroup
© Newsfile
18.06.2024
ATNM
LISTED
XASE
Treatment of Blood Cancers - Biopharma Companies Building out their Pipeline of Solutions
News Preview
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 18, 2024) - Investorideas.com, a go-to investing platform covering biotech and medical technology stocks releases the second of a two-part series looking at developments for the treatment of blood cancers, including AML, featuring Actinium Pharmaceuticals, Inc. (NYSE American:...
Themefolio
Profiler
Peergroup
© Newsfile
17.06.2024
ATNM
LISTED
XASE
Biopharma Stocks Quest for Solutions for Acute Myeloid Leukemia (AML)
News Preview
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 17, 2024) - Investorideas.com, a go-to investing platform, releases the first of a two-part series looking at developments for the treatment of blood cancers. Today's snapshot focuses in on acute myeloid leukemia (AML) and the companies developing innovative solutions, featurin...
Themefolio
Profiler
Peergroup
© PR Newswire
17.06.2024
ATNM
LISTED
XASE
Actinium Presents First Ever Data Demonstrating Actimab-A in Combination with Leading Menin Inhibitors Leads to Anti-Tumor Control and Potent Leukemic Cell Killing in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA Congress
News Preview
- Actimab-A enhances dose-dependent acute myeloid leukemia cell death in KMT2A sensitive acute myeloid leukemia blasts in combination with leading menin inhibitors
- Combination with leading menin inhibitor demonstrates acute myeloid leukemia cell death and significant tumor elimination not achieved with monotherapy
- Menin combination expands ba...
Themefolio
Profiler
Peergroup
© PR Newswire
14.06.2024
ATNM
LISTED
XASE
Actinium Highlights Oral Presentation at EHA 2024 Annual Congress Featuring Improved Outcomes in TP53 Positive Patients Receiving Iomab-B in the Phase 3 SIERRA Trial
News Preview
- Median Overall Survival of 5.49 months observed in patients with a TP53 mutation receiving an Iomab-B led allogeneic bone marrow transplant compared to 1.66 months in patients that did not receive Iomab-B (hazard ratio=0.23, p=0.0002) in the Phase 3 SIERRA Trial
- Long-term efficacy results in patients with active relapsed or refractory acute...
Themefolio
Profiler
Peergroup
© PR Newswire
11.06.2024
ATNM
LISTED
XASE
Actinium Announces Results of Actimab-A + CLAG-M Combination Trial Highlighted in Oral Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting
News Preview
- Novel targeted radiotherapy-based combination being studied as potential backbone therapy potential relapsed or refractory acute myeloid leukemia
- Actimab-A + CLAG-M produced high rates of response, measurable residual disease negativity, bone marrow transplant access and improved survival outcomes in high-risk patients including TP53+ and vene...
Themefolio
Profiler
Peergroup
© PR Newswire
10.06.2024
ATNM
LISTED
XASE
Actinium Highlights Mutation Data from the Phase 3 SIERRA Trial of Iomab-B and Novel Linker Technology to Support Solid Tumor Antibody Radiation Conjugate Development at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting
News Preview
Iomab-B led bone marrow transplant improved survival in patients with high-risk relapsed or refractory acute myeloid leukemia including those with a TP53 mutationIomab-B safely delivered radiation to the target bone marrow at greater amounts than achievable with total body irradiation while sparing healthy non-target organs and enabled 100% acces...
Themefolio
Profiler
Peergroup
© PR Newswire
15.05.2024
ATNM
LISTED
XASE
Actinium to Host KOL Webinar to Discuss Iomab-ACT Commercial CAR T-Cell Therapy Trial Design, Objectives and Potential Market Opportunity
News Preview
- KOL and principal investigator, Dr. Farrukh Awan, Professor of Medicine, Division of Hematology Oncology at University of Texas Southwestern to join Actinium management on the webinar
- Webinar to be held on Monday, May 20th at 8:00 AM ET
NEW YORK, May 15, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or...
Themefolio
Profiler
Peergroup
© PR Newswire
15.05.2024
ATNM
LISTED
XASE
Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients at the EHA 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the Pha
News Preview
- Median Overall Survival of 5.49 months observed in patients with a TP53 mutation receiving an Iomab-B led allogeneic bone marrow transplant compared to 1.66 months in patients that did not receive Iomab-B (hazard ratio=0.23, p=0.0002) in the Phase 3 SIERRA Trial
- Long-term efficacy results in older patients with active relapsed or refractory a...
Themefolio
Profiler
Peergroup
© PR Newswire
13.05.2024
ATNM
LISTED
XASE
Actinium Announces Multiple Abstracts Highlighting its Antibody Radiation Conjugates Iomab-B and Actimab-A and Novel Linker Technology for Solid Tumors Accepted for Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meetin
News Preview
- Iomab-B and Actimab-A are the only targeted radiotherapies in for acute myeloid leukemia addressing different parts of the patient journey
- Improved survival demonstrated with both Iomab-B and Actimab-A in patients with high-risk acute myeloid leukemia including those with a TP53 mutation and prior venetoclax treatment
- Nove...
Themefolio
Profiler
Peergroup
© PR Newswire
07.05.2024
ATNM
LISTED
XASE
Actinium Announces KOL Webinar to Highlight Recently Announced Iomab-ACT Trial with Leading FDA Approved Commercial CAR T-Cell Therapy Being Led by the University of Texas Southwestern
News Preview
Dr. Farrukh Awan, Professor of Medicine, Division of Hematology Oncology at University of Texas Southwestern and Principal Investigator for the trial to join Actinium management for webinarExpansion of Iomab-ACT program with commercial CAR-T supported by ongoing MSKCC clinical trial with success implying a potential billion-dollar market opportun...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
